Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Plethora seeks clearance to begin phase III for PSD-502 in premature ejaculation

Feb. 26, 2007

Orphan drug status awarded to rhPDGF-BB for osteonecrosis of the jaw

Feb. 23, 2007

DiaKine licenses cytokine modulators from U. of Virginia

Feb. 23, 2007

TransTech licenses Novo Nordisk's GKA program

Feb. 23, 2007

Dyax and Genzyme end DX-88 joint venture

Feb. 23, 2007

GCN2 critical for regulating fat metabolism during essential amino acid deprivation

Feb. 23, 2007

Phase IIa study of oleoyl-estrone for obesity completes enrollment

Feb. 23, 2007

Bentley cleared to begin phase II program for Nasulin in India

Feb. 22, 2007

Schering-Plough begins phase I study of Pharmacopeia collaborative compound

Feb. 22, 2007

Bone regeneration seen with tissue repair cells

Feb. 21, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...